(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance on Thursday, despite a rise in costs following the outbreak of war in the Middle East.
Updating on first-quarter trading, the blue chip said all three of its business divisions - injectables, branded and Hikma Rx - were "performing well", with good demand...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE